Literature DB >> 7795891

Narcolepsy and immunity.

E Mignot1, M Tafti, W C Dement, F C Grumet.   

Abstract

Narcolepsy is a neurological disorder known to be associated with human leukocyte antigen (HLA)-DQB1*0602 in humans. In a canine model, the disorder is also genetically linked to a gene of high homology with the human mu-switch-like immunoglobulin (Ig) gene (current LOD score 13.6 at 0% recombination). Since association with HLA or other immune function polymorphic genes (T cell receptor of Ig, mainly) is a hallmark of most autoimmune diseases, it is proposed that autoimmunity may also play a role in the development of narcolepsy. Arguments for and against this hypothesis are reviewed. It is shown that both on the basis of the most recent molecular studies, and because of some of its clinical features, narcolepsy may be an autoimmune disorder. However, neither systemic nor central nervous system (CNS) evidence of any autoimmune abnormality have ever been found. To reconcile this discrepancy, it is suggested that the pathological immune process involved in narcolepsy could be difficult to detect because it is restricted to a very small region of the brain or targets a low abundance neuroeffector. Alternatively, it is possible that a more fundamental relationship is involved between sleep generation and immune regulation. The pathophysiology of narcolepsy may then involve new CNS-immune mechanisms that may shed new light on the sleep process itself.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795891     DOI: 10.1016/0960-5428(94)00043-n

Source DB:  PubMed          Journal:  Adv Neuroimmunol        ISSN: 0960-5428


  24 in total

Review 1.  Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up.

Authors:  C Guilleminault; R Pelayo
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy.

Authors:  Christian Siebold; Bjarke E Hansen; Jessica R Wyer; Karl Harlos; Robert E Esnouf; Arne Svejgaard; John I Bell; Jack L Strominger; E Yvonne Jones; Lars Fugger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

3.  Allergies and Disease Severity in Childhood Narcolepsy: Preliminary Findings.

Authors:  Secil Aydinoz; Yu-Shu Huang; David Gozal; Clara O Inocente; Patricia Franco; Leila Kheirandish-Gozal
Journal:  Sleep       Date:  2015-12-01       Impact factor: 5.849

4.  Narcolepsy in African Americans.

Authors:  Makoto Kawai; Ruth O'Hara; Mali Einen; Ling Lin; Emmanuel Mignot
Journal:  Sleep       Date:  2015-11-01       Impact factor: 5.849

Review 5.  Genetics of narcolepsy and other sleep disorders.

Authors:  E Mignot
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

6.  Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model.

Authors:  M Tafti; S Nishino; M S Aldrich; W Liao; W C Dement; E Mignot
Journal:  J Neurosci       Date:  1996-08-01       Impact factor: 6.167

7.  IgH (mu-switch and gamma-1) region restriction fragment length polymorphism in human narcolepsy.

Authors:  S M Singh; C F George; R N Ott; C Rattazzi; C Guilleminault; W C Dement; E Mignot
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

8.  Neuronal degeneration in canine narcolepsy.

Authors:  J M Siegel; R Nienhuis; S Gulyani; S Ouyang; M F Wu; E Mignot; R C Switzer; G McMurry; M Cornford
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

Review 9.  Narcolepsy in the older adult: epidemiology, diagnosis and management.

Authors:  Sangeeta S Chakravorty; David B Rye
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Medical exposures in youth and the frequency of narcolepsy with cataplexy: a population-based case-control study in genetically predisposed people.

Authors:  Thomas D Koepsell; William T Longstreth; Thanh G N Ton
Journal:  J Sleep Res       Date:  2009-08-31       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.